Intelligent Bio Solutions Projects Strong Revenue Growth, Exceeding $2M in H1 Fiscal 2026

summarizeSummary

Intelligent Bio Solutions Inc. announced preliminary unaudited revenue results, expecting approximately 48% year-over-year growth for fiscal Q2 2026 and over $2 million in total revenue for the first half of fiscal 2026, driven by strong reader and cartridge sales.

check_boxKey Events

• Strong Fiscal Q2 2026 Revenue Growth

  The company expects to report approximately 48% year-over-year revenue growth for the fiscal second quarter ended December 31, 2025.

• H1 Fiscal 2026 Revenue Exceeds $2 Million

  Total revenue for the first half of fiscal 2026 (July-December 2025) is projected to be approximately $2.01 million, representing a 36% increase year-over-year.

• Reader Sales More Than Double

  Fiscal Q2 2026 reader sales are expected to increase by 104% year-over-year, significantly expanding the installed base for recurring cartridge revenue.

• Cartridge Sales Growth

  Fiscal Q2 2026 cartridge sales are expected to increase by 33% year-over-year, demonstrating ongoing consumable demand within the company's business model.

auto_awesomeAnalysis

This 8-K filing reports highly positive preliminary revenue figures, indicating significant operational momentum for Intelligent Bio Solutions. The projected 48% year-over-year revenue growth for fiscal Q2 2026 and over $2 million in total revenue for the first half of the fiscal year are substantial for a company of this size. The doubling of reader sales is particularly important as it expands the installed base, which is foundational to the company's "razor-razorblade" business model, driving future recurring cartridge revenue. This strong performance provides a crucial positive counterpoint to the recent dilutive financing activities, suggesting the capital raised is effectively fueling business expansion and market share capture. Investors should view this as a strong signal of commercial execution and potential for continued growth.